# Product Snapshot - JPMorgan Funds - Thematics - Genetic Therapies

> Audience: country=gb, language=en, role=adv.
> Generated: 2026-11-15T20:49:16.901759993Z.

## Identity

- **Fund Name**: JPMorgan Funds - Thematics - Genetic Therapies
- **Share Class Name**: JPM Thematics - Genetic Therapies A (dist) - USD
- **Product Page**: [Product Page](https://am.jpmorgan.com/gb/en/asset-management/adv/products/jpm-thematics-genetic-therapies-a-dist-usd-lu2053352691)
- **ISIN**: LU2053352691
- **Fund Type**: SICAV
- **Asset Class**: Equity

## OVERVIEW

### Investment objective

To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.



### Registered countries

- **Austria**: 22/10/2019
- **Belgium**: 22/10/2019
- **Cyprus**: 13/11/2025
- **Denmark**: 05/11/2019
- **Finland**: 05/11/2019
- **France**: 22/10/2019
- **Germany**: 22/10/2019
- **Greece**: 22/10/2019
- **Italy**: 06/11/2019
- **Liechtenstein**: 07/07/2020
- **Luxembourg**: 21/10/2019
- **Netherlands**: 22/10/2019
- **Norway**: 05/11/2019
- **Portugal**: 06/12/2023
- **Spain**: 22/10/2019
- **Sweden**: 05/11/2019
- **Switzerland**: 21/10/2019
- **United Kingdom**: 21/10/2019


## Fund facts

- **Bloomberg**: JPGTAUD LX
- **Reuters**: LU2053352691.LUF
- **ISIN**: LU2053352691
- **SEDOL**: BHWTQ61
- **Asset class**: Equity
- **Region**: Global
- **Fund inception date**: 24/10/2019
- **Share class inception**: 24/10/2019
- **Fund currency**: USD
- **Share class currency**: USD
- **ESG Approach**: Thematic [Disclosure 1]
- **SFDR Classification**: Article 8 [Disclosure 2]

## Fund stats

- **NAV  As of 13/11/2026**: USD 125.82 [Disclosure 3]
- **NAV change As of 13/11/2026**: USD -1.86
- **NAV change (%) As of 13/11/2026**: -1.46%
- **12 Month NAV high As of 26/08/2026**: USD 138.06
- **12 Month NAV low As of 18/11/2025**: USD 103.46
- **Fund size As of 13/11/2026**: USD 368.27 Mn

## Fees

### Fees

- **Initial charge**: 5.00%
- **Redemption charge**: 0.00%
- **Ongoing charge**: 1.02%
  - **Annual management fee (included in ongoing charge)**: 0.72%
  - **Operating & administrative expenses (included in ongoing charge)**: 0.30%


## Portfolio managers

### Yazann Romahi

- **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/yazann-romahi/)
- **In the industry**: 27 YEARS
- **With J.P. Morgan**: 23 YEARS
- **Managing this fund**: 7 YEARS

### Aijaz Hussain

- **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/aijaz-hussain/)
- **In the industry**: 11 YEARS
- **With J.P. Morgan**: 10 YEARS
- **Managing this fund**: 7 YEARS

## Performance

### Quarterly rolling 12 months

_As of  30/09/2026_

| Return | 2021/2022 | 2022/2023 | 2023/2024 | 2024/2025 | 2025/2026 |
| --- | ---: | ---: | ---: | ---: | ---: |
| JPM A (dist) - USD | -34.91% | -12.27% | 7.62% | -1.88% | 35.25% |
| Benchmark | -20.66% | 20.80% | 31.76% | 17.27% | 16.75% |
| Excess return (geometric) | -17.96% | -27.38% | -18.32% | -16.33% | 15.84% |

### Calendar year

_As of  31/10/2026_

| Return | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| JPM A (dist) - USD | - | - | - | - | 45.68% | -12.82% | -29.63% | -3.55% | -11.75% | 24.23% | 20.24% |
| Benchmark | - | - | - | - | 16.25% | 18.54% | -18.36% | 22.20% | 17.49% | 22.34% | 11.18% |
| Excess return (geometric) | - | - | - | - | 25.31% | -26.45% | -13.80% | -21.08% | -24.89% | 1.55% | 8.15% |

### Cumulative

_As of  31/10/2026_

| Return | 1 MONTH | 3 MONTHS | 1 YEAR | 3 YEARS | 5 YEARS | SINCE INCEPTION |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| JPM A (dist) - USD | -0.01% | 11.93% | 26.87% | 61.50% | -15.41% | 34.20% |
| Benchmark | -1.64% | -0.14% | 12.33% | 82.93% | 61.80% | 134.80% |
| Excess return (geometric) | 1.65% | 12.09% | 12.95% | -11.72% | -47.72% | -42.84% |

### Annualised

_As of  31/10/2026_

| Return | 3 YEARS | 5 YEARS | SINCE INCEPTION |
| --- | ---: | ---: | ---: |
| JPM A (dist) - USD | 17.33% | -3.29% | 4.28% |
| Benchmark | 22.30% | 10.10% | 12.93% |
| Excess return (geometric) | -4.07% | -12.16% | -7.66% |

 [Disclosure 4]

## Portfolio

### Top holdings

_As of 30/09/2026_

| Name | Sector | Weight |
| --- | ---: | ---: |
| Twist Bioscience | Health Care | 4.5% |
| Iovance Biotherapeutics | Health Care | 3.6% |
| WuXi AppTec | Health Care | 3.5% |
| Charles River Laboratories | Health Care | 3.2% |
| Amgen | Health Care | 3.1% |
| Biogen | Health Care | 3.1% |
| Gilead Sciences | Health Care | 3.1% |
| Krystal Biotech | Health Care | 2.9% |
| Bristol-Myers Squibb | Health Care | 2.9% |
| Johnson & Johnson | Health Care | 2.7% |


### Regional breakdown

_As of 31/10/2026_

| Region | Fund | Benchmark | Deviation |
| --- | ---: | ---: | ---: |
| North America | 70.9% | 67.7% | 3.2% |
| Europe & Middle East ex UK | 13.8% | 10.7% | 3.1% |
| Emerging Markets | 6.9% | 11.2% | -4.3% |
| Japan | 5.1% | 5.1% | 0.0% |
| United Kingdom | 1.4% | 3.1% | -1.7% |
| Pacific ex-Japan | 1.4% | 2.2% | -0.8% |
| Cash | 0.5% | 0.0% | 0.5% |
| Total | 100.0% | 100.0% | 0.0% |


## Documents

- [Factsheet](https://jp.techrules.com/rebrandingPDF/LoadPdf.aspx?ShareClassId=13998&country=GB&lang=EN&paramMIFID=YES)
- [JPMorgan Funds - Thematics - Genetic Therapies - Commentary (A Acc share class)](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/literature/commentary/jpm-thematics-genetic-therapies-commentary-ce-en.pdf)
- [Key Investor Information Document](https://wl.fundsquare.net/serv/down-doc/request?cdClient=jpmorgan&isin=LU2053352691&docTypeCode=KIID&docLang=EN&docCountry=GB)
- [JPMorgan Funds - Prospectus](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/prospectus/jpmorgan-funds-prospectus-ce-en.pdf)
- [JPMorgan Funds - Annual Report](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/annual-report/jpmorgan-funds-annual-report-ce-en.pdf)
- [JPMorgan Funds - Semi-Annual Report ](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/semi-annual-report/jpmorgan-funds-semi-annual-report-ce-en.pdf)

## Disclosures

1. Investments in themes or assets specifically related to sustainability.

2. "Article 8” strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective. “Article 9” strategies have a sustainable investment objective.

3. Net Asset Value of a fund’s assets less its liabilities per Share.

4. Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested. Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees. Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent. The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Indices do not include fees or operating expenses and you cannot invest in them. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.